Abstract Library

#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)

Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Suh M, Cheon G, Lee D,

Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,

#2899 Using Long-Acting Somatostatin Analogue as Adjuvant Therapy for Post Resection Grade 2 Pancreatic Neuroendocrine Tumor: Interim Results from an Ongoing Multicenter Real-World Study in China

Introduction: Surgery was the preferred treatment in patients with resectable pancreatic neuroendocrine tumor (pNET), but recurrent lesion relapsed frequently within a short time. It was controversial whether patients with pNET need adjuvant therapy after surgery.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Shi X

Authors: Shi X, Xu X, Zhang Y, Gao S, Li B,

Keywords: somatostatin analogue, adjuvant therapy, pancreatic neuroendocrine tumor,

#2878 Surgical Management of Neuroendocrine Tumor-Associated Liver Metastases

Introduction: Liver metastasis is common among patients who suffer from neuroendocrine tumors (NETs). Radical surgery is the standard treatment whenever possible but there is still controversies concerning the treatment strategies such as resection of the primary, role of debulking surgery, liver transplantation (LT) and neoadjuvant or adjuvant therapies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bengueddach A, Boudjnene N, Derriche H, Kaid M, Tabeti B,

Keywords: surgery, pancreas, liver metastasis,

#2111 Biliary Neuroendocrine Tumors: A Retrospective Analysis of 28 Patients Since 1991

Introduction: Biliary neuroendocrine tumors represent less than 1% of all neuroendocrine tumors (NETs), and the related clinical study is limited.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zheng Z

Authors: Zheng Z, Chen C, Xie Y, Zheng C, Li B,

Keywords: neuroendocrine tumor, neuroendocrine carcinoma, biliary tract,

#1269 CEA Level, Radical Surgery and CD56 Expression Are Prognostic Factors for Patients with Locoregional Gastrin-independent GNET

Introduction: Gastrin-independent gastric neuroendocrine tumors (GNETs) are highly malignant. Radical resections and lymphadenectomy are considered to be the only possible curative treatment for these tumors. However, the prognosis of gastrin-independent GNETs is not well defined.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Zhao H

Authors: Li Y, Zhao H, Cai J,

Keywords: Gastrin-independent GNET, Prognosis, CEA, Surgery, CD56 expression.,